Lipocine (NASDAQ:LPCN) Research Coverage Started at Alliance Global Partners
Alliance Global Partners began coverage on shares of Lipocine (NASDAQ:LPCN – Free Report) in a report released on Tuesday, Benzinga reports. The firm issued a buy rating and a $10.00 target price on the specialty pharmaceutical company’s stock. Separately, StockNews.com upgraded shares of Lipocine from a hold rating to a buy rating in a research […]
27 Sep 16:27 · The Markets Daily